BOSTON, Aug. 21 /PRNewswire/ -- Surface Logix is pleased to announce
the appointment of Leland Webster, Ph.D., M.B.A., as Vice President,
Corporate Development. As a member of the management team, Dr. Webster will
primarily be responsible for leading the development and execution of
Surface Logix's business strategy and corporate partnering activities. Dr.
Webster will also have responsibility for corporate communications.
"I am extremely pleased to welcome Leland to the Surface Logix
management team. I look forward to working with him as we near Phase IIa
proof of concept for our two lead compounds, SLx-2101 and SLx-4090, the
achievement of which will result in significant value creation in the
context of partnering and funding discussions," said Jim Mahoney, CEO of
Surface Logix. "Leland's scientific background combined with his business
training and 11 years of biotechnology industry experience in business
development brings a valuable mix of skills and experience to our company
as we continue to both advance our clinical programs and exploit our core
Pharmacomer(TM) Technology."
Prior to joining Surface Logix, Dr. Webster led business development at
ImmunoGen, Inc., most recently as an Executive Director. Previously, he
held positions of increasing responsibility in business development at
Vertex Pharmaceuticals. Before that, Dr. Webster was a Senior Analyst at
MPM Capital L.P.
Dr. Webster holds a B.A. in Biological Sciences from Northwestern
University and a Ph.D. in Biochemistry from the University of Pennsylvania,
and served as a Damon Runyon-Walter Winchell postdoctoral fellow in the
Department of Biological Chemistry and Molecular Pharmacology at the
Harvard Medical School. Dr. Webster also earned an M.B.A. from the MIT
Sloan School of Management.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create and develop novel small molecule drugs (NCEs) with superior
intrinsic drug- like properties that are clearly differentiated from
competitive products. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com .
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Leland Webster, Ph.D., M.B.A, Vice President,
Corporate Development of Surface Logix Inc., +1-617-746-8520, or
Kari Watson of MacDougall Biomedical Communications Inc.,
+1-508-647-0209, kwatson@macbiocom.com, for Surface Logix Inc.
|
